SFL
15.10.2020 20:39:07 CEST | Business Wire | Press release
Regulatory News:
SFL (Paris:FLY)
Rental income: €137.7m
Consolidated revenue by business segment (€000’s) |
|||
|
|
2020
|
2019
|
Rental income |
137,667 |
149,070 |
|
o/w |
Paris Central Business District |
114,845 |
121,877 |
|
Paris Other |
20,996 |
25,786 |
|
Western Crescent |
1,826 |
1,407 |
Other revenue |
0 |
0 |
|
Total consolidated revenue |
137,667 |
149,070 |
|
Consolidated rental income for the first nine months of 2020 amounted to €137.7 million, down €11.4 million or 7.6% from the €149.1 million reported for the same period of 2019.
- On a like-for-like basis (excluding changes in consolidation scope affecting period-on-period comparisons), rental income contracted by €3.5 million. The 2.6% decline was due to the effects of the Covid-19 crisis, which led to rent holidays being granted to tenants of retail units and the closure of the Edouard VII and #cloud.paris conference centres as well as the Indigo hotel. Excluding the effects relating to the conference centres, the Indigo hotel and the Edouard VII car park, representing a reduction of €4.6 million in top-line rental income and of €2.8 million in net rental income, the like-for-like change in the top-line was a positive €1.1 million (0.8%).
- Rental income from units being redeveloped or renovated in the periods concerned was down by €4.7 million, due to the renovation of several floors that were vacated in late 2019 and early 2020, mainly in the 103 Grenelle and Edouard VII buildings.
- Lastly, period-on-period comparisons were adversely affected by the €3.2 million in income received from various penalties in 2019.
The rent recovery rate for the second and third quarters of 2020 currently stands at a very satisfactory 96% overall, and at 100% for office units. Negotiations are currently in progress with the remaining tenants that are behind with their rent, and agreements are imminent in the vast majority of cases.
Business review
Despite the Covid-19 crisis, which triggered a 46% drop in the Paris region’s rental market volume over the first nine months of 2020, the Group signed leases on around 18,000 sq.m. during the period, including 10,000 sq.m. of office space, on very good terms. They included the pre-letting of 85% of the 83 Marceau building which is currently being redeveloped and will be delivered in the second half of 2021.
The new office leases were signed at an average nominal rent of €867 per sq.m., corresponding to an effective rent of €754 per sq.m. These prices attest to the Paris rental market’s resilience and the very high quality of the Group’s properties.
The physical occupancy rate for revenue-generating properties stood at 94.7% at 30 September 2020 compared with 97.4% at 31 December 2019. The remaining vacant units mainly comprise 5,700 sq.m. of newly renovated offices in the 103 Grenelle building which have recently been delivered and the Le Vaisseau building in Issy-les-Moulineaux. The EPRA Vacancy Rate was 4.7% at 30 September 2020 versus 1.6% at 31 December 2019.
No properties were purchased or sold during the first nine months of 2020.
Financing
As part of its active debt management strategy, in early September SFL launched a tender offer on its two notes issues maturing in November 2021 and November 2022. The €160.7 million worth of notes tendered to the offer were retired, allowing SFL to reduce its future average borrowing costs and extend the average maturity of its debt.
SFL’s consolidated net debt at 30 September 2020 amounted to €1,874 million, compared with €1,732 million at 31 December 2019, representing a loan-to-value ratio of 24.3% based on the portfolio’s appraisal value at 30 June 2020. The average cost of debt after hedging was 1.5% and the average maturity was 4.7 years. At end-September 2020, the interest coverage ratio stood at 5.2x.
In addition, SFL had €1,040 million in undrawn lines of credit at 30 September 2020.
Management of the Covid-19 health crisis
From the onset of the crisis, SFL took all necessary measures to limit the pandemic’s effects on its business and results:
- All the office buildings remained open and available for use by tenants and the necessary health protection measures deployed in the buildings’ common areas were regularly updated to comply with successive government directives.
- The conference centres (Edouard VII and #cloud.paris) and the Indigo hotel (Edouard VII) that were closed during lockdown were re-opened in July, despite the very sluggish business environment.
- Government measures concerning very small businesses and small retail outlets were applied and tenant requests for help were managed on a case-by-case basis in order to provide them with the necessary support as far as possible, for example by allowing them to defer payment of their second quarter rent.
- Property leasing activities continued, keeping a close watch on the rental market.
- Agreements were signed with the general contractors working on the main redevelopment projects currently in progress.
- The Group’s financial liquidity was strengthened.
To ensure business continuity while also protecting employees, all of SFL’s teams worked from home during the lockdown and no employees were furloughed. Since the lockdown was lifted, they have been gradually returning to the office while benefiting from flexible office/home working arrangements.
SFL has also contributed to the collective effort to fight the pandemic by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people.
About SFL
Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.
Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA
S&P rating: BBB+ stable outlook
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005964/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
